Citigroup began coverage on shares of Healthequity (NASDAQ:HQY) in a research report released on Thursday morning. The firm issued a buy rating on the stock.

Several other research analysts have also recently weighed in on the company. Zacks Investment Research upgraded Healthequity from a hold rating to a buy rating and set a $58.00 price objective on the stock in a research report on Wednesday, October 11th. BidaskClub raised shares of Healthequity from a sell rating to a hold rating in a research report on Thursday, September 28th. Cantor Fitzgerald reissued a buy rating and issued a $56.00 target price on shares of Healthequity in a research report on Tuesday, December 5th. Robert W. Baird restated a hold rating on shares of Healthequity in a research note on Thursday, September 21st. Finally, Oppenheimer reaffirmed a buy rating and set a $61.00 price target on shares of Healthequity in a research report on Wednesday, September 6th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $58.33.

Healthequity (NASDAQ:HQY) traded up $0.74 during trading on Thursday, hitting $48.02. The stock had a trading volume of 396,800 shares, compared to its average volume of 469,100. Healthequity has a 52 week low of $37.62 and a 52 week high of $55.31. The firm has a market capitalization of $2,868.60, a P/E ratio of 64.89, a price-to-earnings-growth ratio of 1.95 and a beta of 1.74.

Healthequity (NASDAQ:HQY) last announced its earnings results on Tuesday, December 5th. The company reported $0.17 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.13 by $0.04. The company had revenue of $56.80 million for the quarter, compared to analyst estimates of $55.27 million. Healthequity had a return on equity of 14.47% and a net margin of 21.08%. The firm’s quarterly revenue was up 31.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.10 earnings per share. equities analysts anticipate that Healthequity will post 0.71 EPS for the current fiscal year.

In other Healthequity news, VP Darcy G. Mott sold 9,500 shares of the firm’s stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $47.91, for a total value of $455,145.00. Following the transaction, the vice president now directly owns 96,500 shares of the company’s stock, valued at approximately $4,623,315. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Ashley Dreier sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $50.97, for a total transaction of $509,700.00. Following the completion of the transaction, the vice president now directly owns 15,652 shares in the company, valued at $797,782.44. The disclosure for this sale can be found here. Insiders have sold 1,445,573 shares of company stock worth $75,519,359 in the last three months. 29.00% of the stock is currently owned by company insiders.

Several institutional investors have recently modified their holdings of the company. Zions Bancorporation acquired a new position in Healthequity during the third quarter valued at approximately $119,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Healthequity by 105.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,544 shares of the company’s stock valued at $127,000 after purchasing an additional 1,308 shares in the last quarter. Riverhead Capital Management LLC increased its stake in shares of Healthequity by 75.3% in the 2nd quarter. Riverhead Capital Management LLC now owns 2,629 shares of the company’s stock valued at $131,000 after purchasing an additional 1,129 shares during the last quarter. Oppenheimer Asset Management Inc. increased its stake in shares of Healthequity by 7.7% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 2,686 shares of the company’s stock valued at $134,000 after purchasing an additional 191 shares during the last quarter. Finally, D.A. Davidson & CO. raised its holdings in shares of Healthequity by 15.2% during the 2nd quarter. D.A. Davidson & CO. now owns 3,326 shares of the company’s stock worth $165,000 after buying an additional 439 shares in the last quarter. 98.27% of the stock is owned by institutional investors.

WARNING: This piece was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2018/01/05/healthequity-hqy-coverage-initiated-by-analysts-at-citigroup.html.

Healthequity Company Profile

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Analyst Recommendations for Healthequity (NASDAQ:HQY)

Receive News & Stock Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related stocks with our FREE daily email newsletter.